Results 141 to 150 of about 1,580 (184)

Hemodynamic and symptomatic response in hypertrophic obstructive cardiomyopathy patients on myosin inhibitor therapy. [PDF]

Front Cardiovasc Med
Seuthe K, Feidakis A, Nies R, Brüwer M, Pennig L, Kaya K, Ten Freyhaus H, Baldus S, Pfister R.   +8 more
europepmc   +1 more source

Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM. [PDF]

Circ Genom Precis Med
Bilen O, Adler A, Bastiaenen R, MacNamara JP, Paratz E, Maor E, Arad M, Gold M, Patel N, Pruett C, Burford E, Arora G, Maksabedian Hernandez EJ, Han X, Schuler P, Sandler B, Li L, Tian D, Arora P, COLLIGO-HCM investigators.   +19 more
europepmc   +1 more source

Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy

Australian prescriber
openaire   +3 more sources

Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American College of Cardiology, 2021
Background: EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) demonstrated that mavacamten, a cardiac myosin inhibitor, improves symptoms, exercise capacity, and left ...
Steven J Lester, Perry M Elliott, Sherif F Nagueh   +2 more
exaly   +2 more sources

Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy

American Journal of Physiology - Heart and Circulatory Physiology, 2021
Mavacamten is a pharmaceutical that binds to myosin, and it is under investigation as a therapy for some forms of heart disease. We show that mavacamten reduces isometric tension and Ca2+ sensitivity of contraction in skinned myocardial strips from a ...
Peter O Awinda, Katarzyna Kaźmierczak, Danuta Szczesna‐Cordary   +2 more
exaly   +2 more sources

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology, 2020
BACKGROUND: Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience a high burden of symptoms; however, there are no proven pharmacological therapies.
Carolyn Y Ho, Jay M Edelberg, Daniel Jacoby   +2 more
exaly   +3 more sources

Effect of Beta-Blocker Therapy on the Response to Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]

European Journal of Heart Failure, 2023
AIMS: In the EXPLORER-HCM trial, mavacamten improved exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten effects on the primary endpoint, a composite of peak oxygen consumption (VO2 ) and New York ...
Matthew T Wheeler, Perry M Elliott
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Mavacamten—A Targeted Therapy for Hypertrophic Cardiomyopathy

Journal of Cardiovascular Pharmacology, 2023
Abstract: The pathophysiology of hypertrophic cardiomyopathy is primarily comprised of dynamic left ventricular outflow tract obstruction, mitral regurgitation, and diastolic dysfunction. Symptoms such as dyspnea, angina, or syncope can occur because of left ventricular (LV) hypertrophy and reduced LV cavity size.
Ashley, Schenk, Nathan, Fields
openaire   +2 more sources